How CEOs optimise their sleep routine
As CEO of Uber Technologies, Dara Khosrowshahi operates in a world with an abundance of screentime; unsurprisingly, that used to be part of his resting regimen. 'I used to wear a smart health tracker that rated my sleep, and I absolutely loved it,' he says. 'As someone who is really into data, getting detailed insights was right up my alley.' But eventually, he says, 'I got a little too into it, competing with myself every night'. These days, he employs a completely different sleep hack. 'I've gone back to falling asleep the old-fashioned way – no tracking, just reading.' His advice? 'Get rid of the screens, and you'll be ahead of the game.'
Thirty years ago, Sam Calagione helped kick off America's craft beer obsession when he started Dogfish Head Craft Brewery in Rehoboth Beach, in the US state of Delaware. (In 2019, the Boston Beer Company acquired it for US$300 million.) Calagione works out for 60 minutes every day, in part to be properly worn out at night. As it happens, he says, 'our best-selling beer is called 60 Minute IPA'. But his real sleep tip is to relax before bed. 'I take a half-hour bath every evening, below a giant photograph of Andre 3000 playing a flute. It calms me as I read, but it freaks my wife, Mariah, out a bit, which may be why we have separate bathrooms,' he says.
'I've been lucky in that I've always been able to sleep, despite my 20 espressos a day,' jokes Konstantin Sidorov, CEO of the London Technology Club, a UK-based venture capital fund. (It's most recent launch, in May, was the US$250 million VC Secondary Fund.) 'I typically have a late, sociable dinner with fine wine, which I'm sure helps.' On the opposite end of the spectrum, another of his sleep secrets is staying active. 'No matter how busy my schedule is, I always work out at least twice a week – wherever I am in the world.' Sidorov also takes advantage of his hectic travel schedule to nap: 'I have no problem sleeping on a plane, travelling to and from our investor hubs in Hong Kong and Dubai.'
In 2024, Rayni Williams, CEO and co-founder of The Beverly Hills Estates, closed over US$1.3 billion in house sales; her clients include actors Jeremy Renner and Angelina Jolie, and developer Bruce Makowsky. Sleep is non-negotiable, she says, and she's developed a very specific routine to help her maximise it. 'I take magnesium, zinc and ATP (a cellular energy supplement), along with a cortisol balancer to help regulate stress levels.' And that's just the start. 'A relaxing shower, followed by a full skincare and self-care regimen, helps signal to my body that it's time to rest,' she says. 'I'll often journal to clear my mind and always incorporate deep breathing work to centre myself before bed. A few nights a week, I use my Shani Darden red-light mask. This helps boost collagen; it only needs 15 minutes, so I will do a meditation simultaneously.'
Tony Tjan is the CEO of MiniLuxe, a national nail-care brand that offers nail and body services and non-toxic products; it brought in over US$26 million in revenue in 2024. Sleep is not Tjan's speciality, but he says he's been trying to be better. 'The biggest shift has been a routine that includes a micro session of meditation with a sound bowl,' he says. 'Then, earlier to bed and super early to rise. I'll never forget a saying that Tom Brady once shared with me: 'You can't be soaring with the eagles in the morning if you are hooting with owls late at night!''
A NEWSLETTER FOR YOU
Friday, 2 pm Lifestyle
Our picks of the latest dining, travel and leisure options to treat yourself.
Sign Up
Sign Up
The Carlsberg Group has been brewing beer in Copenhagen since the 1840s. Two years ago, Jacob Aarup-Andersen took over as CEO of Carlsberg, whose 2024 reported earnings hit almost US$11 billion. One of his current priorities is expanding the company's non-alcoholic beer portfolio, which complements his own personal focus on health: 'If I wake up earlier than planned, I don't fight it. I get up and get going. Trying to squeeze in more sleep often leaves me groggy and throws off my rhythm for days.' Instead, he says, 'I use that extra time to work out or run, which helps me reset and sleep deeply the following nights. It's about listening to your body.'
'This might sound counterproductive, but my best hack for a good night's sleep is to make time for a nap – at least 40 minutes a day,' says Michael Kirban. He's the co-founder and executive chairman of the Vita Coco Company, a popular coconut water brand. In 2024, Vita Coco hit US$516 million in sales of its boxed beverages. About naps, Kirban continues: 'They help me turn my brain off more easily when I go to bed at night.'
Peter McGuinness knows his way around major food companies. In 2022 he became CEO of the plant-based meat company Impossible Foods, following a run as president of popular yoghurt company Chobani. What he's not so good at is optimising sleep. 'That's not a good thing to brag about,' he says. 'I'm not philosophically against sleep. I just don't do a good job.' Part of the reason, he says, is his busy travel schedule, which has him navigating time changes: 'I'm on a plane a lot. It's enough to be disruptive and throw your biorhythms off.' McGuinness has also learned to function without a lot of sleep. 'I just kind of power through it. But I'm not too old to learn. So I will make it a priority, or more of a priority.'
Amina Belouizdad Porter is CEO of PS, which stands for Private Suite, and operates private terminals at both LAX and ATL that let clients go through private security systems before being escorted to planes. Even as she expands her company nationally, Porter prioritises her downtime. 'We've finally moved past bragging about no sleep. I aim for a consistent seven to eight hours every night. It's non-negotiable.' BLOOMBERG
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
2 days ago
- Business Times
AstraZeneca vows to spend US$50 billion on US manufacturing, development
[MUNICH/WASHINGTON] AstraZeneca plans to invest US$50 billion in the US before 2030, becoming the latest European pharma company to ratchet up spending in the country ahead of potential tariffs on imported medicines. The investment will go towards manufacturing as well as research and development, Astra said in a statement. It includes US$4 billion for a new facility in Virginia that will make drugs for chronic diseases, Kevin Hassett, director of the US National Economic Council, said on Monday (Jul 21) at an event in Washington, DC. 'With the completion of this investment, substantially all of AstraZeneca's pharmaceuticals sold at the United States will be produced in the United States,' Hassett said. Astra's announcement comes as European drug companies rush to highlight their significant footprints in the US in hopes of mitigating the impact of any potential tariffs from US President Donald Trump. Astra already announced plans in November, a week after Trump's election, to invest US$3.5 billion in the US by the end of 2026, noting at the time that it employs nearly 18,000 people in the country. Since then, European competitors have touted even larger spending plans. Switzerland's Novartis in April announced plans for US$23 billion in US-based infrastructure spending, while cross-town rival Roche Holding said it would invest US$50 billion. In May, French drugmaker Sanofi announced intent to invest at least US$20 billion in the US by 2030. Pascal Soriot, who's been chief executive officer of Astra since 2012, has also urged tariff restraint. This spring, he recommended that US officials exempt medicines from tariffs, arguing that tax incentives are a better way to attract investment in drug development and manufacturing. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Trump has proposed various timelines for tariffs on pharmaceuticals, most recently floating duties that would be imposed as soon as Aug 1. The president said that he expects to give companies a year to bring manufacturing to the US before imposing tariffs as high as 200 per cent. Meanwhile, Soriot has raised concerns in the UK about his commitment to the home country. He has long complained about the UK's regulatory environment, which he says is a threat to hold back the UK from staying competitive with the US and China. In January, Astra abandoned plans for a £450 million (S$777 million) vaccine manufacturing plant in Liverpool. The company operates 17 manufacturing sites in 12 US states. Earlier this month, British paper The Times reported that Soriot is considering moving the company's stock listing to the US. That would be a major blow to the UK's equity markets, which have endured similar defections from other companies in recent years. Under Soriot's leadership, Astra's market value has more than tripled as the company has become a global powerhouse in cancer medicines. It's also built up a significant drug pipeline for other areas including cardiovascular, renal and metabolic diseases. BLOOMBERG
Straits Times
3 days ago
- Straits Times
Trial of new dengue vaccine begins recruitment for child participants in Singapore
Find out what's new on ST website and app. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying (left), and Dr Zhong Youjia, another investigator on the study. SINGAPORE – A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine in children aged two to 17. Developed by US-based pharmaceutical firm MSD, V181 is a single-dose vaccine that aims to provide protection against all four serotypes, or strains, of the dengue virus. Phase three clinical trials are typically the last stage of testing before a drug's details and clinical trial results are submitted to the regulatory authorities for approval. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying, noted that V181 is a live-attenuated vaccine, which uses weakened versions of all four dengue serotypes. 'Using the weakened forms of all these four dengue serotypes stimulates a human immune response to create protection against dengue infection in future,' said Prof Chia, who also heads the National Centre for Infectious Diseases Research Office. The new study here hopes to recruit at least 700 healthy children between the ages of two and 17, including both those who have previously contracted dengue and those who have never had the disease, said Dr Zhong Youjia, another investigator on the study. This particular study focuses on children as they are more vulnerable to dengue and are also at a greater risk of severe infection, said the associate consultant at National University Hospital's (NUH) Khoo Teck Puat – National University Children's Medical Institute. Side effects from the vaccine have been mild and short-lived, said Prof Chia, noting that they include muscle aches and fatigue. Children enrolled in the study will be randomly chosen to get a single shot of either the vaccine or a placebo. 'There have been no serious adverse events linked to vaccination with V181 to date, and the previous trials actually have shown a very good and favourable safety profile,' Prof Chia said. In Singapore, the study is being conducted at NUH and Tan Tock Seng Hospital, which have already started recruiting participants. Only a handful of children have been recruited so far for the study here, which began in June, said Dr Zhong. A third recruitment site, KK Women's and Children's Hospital, is also in the works. As at July 12, there have been 2,816 dengue cases recorded here in 2025, according to figures from the National Environment Agency (NEA). In May, NEA noted that the number of dengue cases recorded here between January and May 2025 has dropped by about 74 per cent from the same period in 2024. Worldwide, the study aims to enrol about 12,000 healthy children, also between the ages of two and 17, who will receive either a single dose of V181 or a placebo. It aims to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific, including Indonesia, Malaysia and the Philippines. Developing effective dengue vaccines has been difficult as the four serotypes are effectively four different viruses, said Prof Chia. While getting infected by one serotype grants lifelong protection against that particular strain, it provides only short-term protection against the other three, she said. This short-term protection eventually wanes, she noted, adding that those who contract dengue more than once risk antibody-dependent enhancement – a phenomenon where antibodies that are generated due to a vaccine or prior infection actually increase the severity of an infection. Dr Zhong noted this can result in dengue shock syndrome, otherwise known as dengue haemorrhagic fever, a potentially life-threatening complication with symptoms including circulatory failure. Designing a dengue vaccine has been challenging as it has to take into account this phenomenon, Prof Chia said. Should the trials be successful and the vaccine meet regulatory requirements, V181 could be commercially available as early as within the next three to five years, said Dr Zhong. Dr Paula Annunziato, senior vice-president for infectious diseases and vaccines global clinical development at MSD Research Laboratories, noted that half the world's population live in areas at risk for dengue. 'If successful, V181 could provide an important single-dose option for at-risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe,' she said. Dengvaxia, developed by Sanofi Pasteur, is currently the only dengue vaccine approved for use in Singapore. However, it is available only for those between 12 and 45 years old who have previously been infected and poses an increased risk of causing severe dengue in those who have never been infected. In May 2024, another quadrivalent vaccine, Qdenga, received pre-qualification from the World Health Organisation (WHO) – a process that aims to ensure the safety and efficacy of treatments – with WHO recommending the vaccine's use for children aged between six and 16 in dengue-prone areas. Developed by Japanese pharmaceutical company Takeda, Qdenga was made available in Malaysia in June 2024 . Qdenga was submitted for approval here in 2022. However, the following year, the Health Sciences Authority said Takeda had withdrawn its application. The authority said then that the company could submit another application with further clinical data on the vaccine meeting the 'required safety, efficacy and quality standards for use locally'.
International Business Times
6 days ago
- International Business Times
Top Cloud Engineer Shaik Abdul Kareem Breaks New Ground with AI-Based Security Framework of Enterprise Infrastructure
The Asia-Pacific region's technology sector continues to benefit from groundbreaking innovations developed by leading experts in the United States. Among these influential figures, Shaik Abdul Kareem, a US-based cloud engineering specialist, has made remarkable contributions that are particularly valuable for Asian enterprises navigating complex digital transformation challenges. His work in AI engineering and advanced cloud infrastructure serves as a crucial resource for organizations across our rapidly evolving regional technology landscape. Revolutionary Contributions to Cybersecurity Technology Abdul Kareem's most significant recent achievement involves his development of neural transformer-based models specifically engineered for cybersecurity network traffic analysis. In contrast to the classical signature-based detection mechanisms, the proposed solution by Shaik Abdul Kareem uses the Natural Language Processing methods to categorize the sequence of network packets and detect the zero-day threats with the highest precision rates ever. Abdul Kareem's patented system includes sophisticated components: a data collection module, preprocessing unit, feature extraction module, machine learning engine, real-time analysis engine, automated response module, and threat data integration module. This comprehensive approach addresses the fundamental limitations of traditional cybersecurity methods by leveraging AI and ML to detect subtle anomalies, reduce false positives, and process massive data volumes efficiently. The AI-based models created by Shaik Abdul Kareem are a paradigm change in terms of reactive to proactive security strategies. His systems are capable of detecting subtle anomalies that conventional cybersecurity solutions miss entirely, providing organizations with advanced threat protection capabilities that adapt to emerging security challenges in real-time. The AI Innovation in Transforming Healthcare Infrastructure Shaik Abdul Kareem's expertise extends significantly into healthcare technology, where his cloud-based AI solutions are revolutionizing patient care delivery. His latest research article, Cloud-Based AI Solutions in Public Health Surveillance and Crisis Management, shows how AI and Machine Learning models that run on cloud systems can improve public health surveillance in terms of predicting disease outbreaks and managing healthcare resources in a more efficient way. The applied value of the healthcare innovations of Abdul Kareem is immense. His AI/ML models can help hospitals and medical facilities to anticipate energy needs depending on the number of patients, the use of equipment, and other external factors, such as weather conditions, and optimize energy distribution without affecting the critical functions. Healthcare administrators report significant reductions in operational costs and carbon footprints following implementation of Abdul Kareem's energy optimization frameworks. Shaik Abdul Kareem has developed solutions that change the face of the public health infrastructure, making it better prepared and responsive to health crises by keeping it efficient. His work shows how the cloud-based AI and ML solutions can reshape the infrastructure of the public health sector and ultimately save lives and decrease the load on healthcare resources. Innovative Smart City Healthcare Integration The fact that Abdul Kareem can span the gap between various technological fields is evidenced by his vision of integrated smart city healthcare systems. His research explores how integrating healthcare into smart city infrastructures can improve patient care and public health outcomes through IoT device integration, AI-powered predictive analytics, and mobile health applications that expand access to care. The case studies in the implementations of Shaik Abdul Kareem in the large urban centers show that there are measurable improvements in the healthcare delivery. Cities utilizing his frameworks report enhanced emergency response times, improved resource allocation, and better patient outcomes through real-time health monitoring and predictive analytics systems. The healthcare models of the smart city created by Abdul Kareem show how technology can transform the delivery of healthcare in urban areas. His implementations in cities like Barcelona, Singapore, and London showcase advancements in action, demonstrating how technology is reshaping urban healthcare delivery through integrated IoT systems and predictive analytics. Healthcare Security Innovation with Blockchain The newest publication of Abdul Kareem tries to resolve important issues in healthcare data management by integrating blockchain technology. In his research paper, Blockchain Applications in Electronic Health Records (EHRs), he addresses the issues of scalability, regulatory compliance, and cost implications of using blockchain to implement healthcare systems. Shaik Abdul Kareem advocates for large-scale pilot programs, cross-border data exchange protocols, and standardized frameworks to support blockchain integration in healthcare. His solutions will guarantee data integrity, patient privacy, and regulatory compliance and allow smooth sharing of information within healthcare networks. The blockchain frameworks Abdul Kareem has created offer unmatched security and transparency of sensitive healthcare data. His efforts are already laying the framework of the next-generation electronic health record systems that will be both secure and interoperable. Energy Optimization and Sustainability Solutions In the research paper titled Optimizing Energy Usage in Hospitals and Medical Centers with AI/ML: Ensuring Continuous Critical Operations and Reducing Costs and Carbon Footprint, Shaik Abdul Kareem discusses how Artificial Intelligence and Machine Learning can be used to forecast energy requirements using patient occupancy, equipment use, and external conditions such as weather conditions. The AI/ML system created by Abdul Kareem balances the energy distribution without affecting important operations. The paper shows considerable savings in operation expenses and carbon footprints, with extensive experimental findings and deployment structure. Healthcare facilities implementing Abdul Kareem's energy optimization solutions report substantial cost savings while maintaining the highest standards of patient care. Industry Awareness and Influence The works by Abdul Kareem have drawn the attention of the industry players and academic institutions. He is a Treasurer of the IEEE Atlanta Young Professionals group, and a Senior Member of IEEE, which demonstrates the respect his colleagues have towards his technical knowledge and leadership skills. The creative nature of Shaik Abdul Kareem in addressing complex infrastructure problems is always identified by the technology executives. Companies that have adopted his AI-based predictive models and AI/ML-driven frameworks indicate that they have minimized downtime in their operations by more than 30 percent and have improved their real-time security monitoring. His publications have appeared in leading technology magazines, and in recent publications he has been credited with making contributions to cloud computing advancements and AI-based security services. Abdul Kareem's research has been recognized by leading academic journals and international conferences, establishing him as a thought leader in cloud infrastructure and cybersecurity. Neural Transformers for Zero-Day Threat Detection Shaik Abdul Kareem's groundbreaking research paper "Neural Transformers for Zero-Day Threat Detection in Real-Time Cybersecurity Network Traffic Analysis" presents a novel approach to detecting zero-day threats in real-time network traffic using Neural Transformers originally designed for Natural Language Processing. The transformer model created by Abdul Kareem is specifically adjusted to the classification of network packet sequences and the identification of anomalies. The practical data prove that the transformer-based model proposed can perform much better in the zero-day threat detection than the conventional systems. This research has been recognized by the Social Science Research Network, with Abdul Kareem's paper listed among the top downloads in cybersecurity research. The Implications of the Work of Abdul Kareem in the Future Shaik Abdul Kareem's ongoing research continues to push the boundaries of what's possible in cloud infrastructure and AI-powered security systems. His work on generative AI applications in healthcare, energy optimization in medical facilities, and blockchain-based security frameworks positions him at the forefront of multiple converging technology trends. The flexibility and scalability of the solutions offered by Abdul Kareem are especially useful to organizations of any size. His models have been effectively applied in different sectors such as healthcare and finance, telecommunications and government services, which proves the universality of his innovative solutions. As cybersecurity threats continue to evolve and healthcare systems face increasing digitalization pressures, Shaik Abdul Kareem's contributions provide essential tools for organizations seeking to protect their digital assets while improving operational efficiency. His contribution is an important connection between advanced research in the field of AI and viable, implementable technologies that solve real problems. The technological frameworks and methodologies developed by Abdul Kareem are establishing new industry standards and influencing how organizations worldwide approach cloud security, healthcare technology integration, and smart city infrastructure development.
